Phuturdex › Diseases › Interstitial lung disease
Drugs in development · updated 30 October 2026
Interstitial lung disease: drugs in development
As of 30 October 2026 there are 58 active clinical trials (recruiting or ongoing, phases I–III) on 65 drugs for interstitial lung disease. 33 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Mosliciguat | III | 3 | NCT07816185 |
| Treprostinil Palmitil Inhalation Powder | III | 3 | NCT07234032 |
| [18F]FAPI-74 | III | 1 | NCT07613099 |
| BMS-986278 | III | 1 | NCT06025578 |
| CABA-201 | II–III | 1 | NCT06328777 |
| L606 | III | 1 | NCT07285655 |
| [68Ga]CBP8 | II | 2 | NCT07572383 |
| ADSC01 | I–II | 1 | NCT06574581 |
| Amlitelimab | II | 1 | NCT06195072 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT05828953 |
| AP01 | II | 1 | NCT06329401 |
| Efzofitimod | II | 1 | NCT05892614 |
| GenisteinBIO 300 | II | 1 | NCT07323732 |
| GM-CSFGranulocyte-Macrophage Colony-Stimulating Factor | II | 1 | NCT03630211 |
| Golidocitinib | II | 1 | NCT07737249 |
| Hymecromone | II | 1 | NCT06325696 |
| INS018_055 | II | 1 | NCT05975983 |
| LAM-001 | II | 1 | NCT05798923 |
| LTI-03 | II | 1 | NCT06968845 |
| NCR101 | I–II | 1 | NCT06825169 |
| PIPE-791 | II | 1 | NCT07284459 |
| ROC-101 | II | 1 | NCT07175038 |
| Senicapoc | II | 1 | NCT06714123 |
| Tibulizumab | II | 1 | NCT06843239 |
| Tulisokibart | II | 1 | NCT05270668 |
| TX000045 | II | 1 | NCT07473700 |
| BMS-986553 | I | 1 | NCT07873931 |
| GSK4527363 | I | 1 | NCT06576271 |
| ICF004 | I | 1 | NCT07719218 |
| Pacebo | I | 1 | NCT07719218 |
| REGEND001 | I | 1 | NCT06998706 |
| RJ026 | I | 1 | NCT06992661 |
| 68Ga-FAPI-46 | Early I | 1 | NCT05365802 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BelimumabBenlysta® | II–III | 4 | NCT05878717 |
| NerandomilastBI 1015550, Jascayd® | III | 4 | NCT07201922 |
| DexamethasoneDexametasone, Dextenza | III | 2 | NCT07828054 |
| TreprostinilTyvaso Dpi®, Yutrepia® | III | 2 | NCT04905693 |
| NintedanibNintedanib Accord®, Vargatef® | III | 1 | NCT06297096 |
| TocilizumabTociluzumab, Avtozma | III | 1 | NCT06297096 |
| Gadoterate MeglumineDotarem | II | 2 | NCT07572383 |
| HydroxychloroquineSovuna®, Plaquenil® | II | 2 | NCT07443436 |
| AbataceptOrencia® | II | 1 | NCT04925375 |
| AlemtuzumabCampath, Lemtrada® | II | 1 | NCT03630211 |
| AmitriptylineElavil® | II | 1 | NCT05120934 |
| Anti-Thymocyte Globulin | II | 1 | NCT03630211 |
| AzithromycinAzasite®, Zithromax® | II | 1 | NCT07443436 |
| Bevacizumabavastin, MVASI | II | 1 | NCT07420439 |
| CarboplatinCarboplatine, Paraplatin | II | 1 | NCT07420439 |
Sorted by most advanced phase and number of active trials. Showing 15 of 32 drugs.
All 65 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Idiopathic pulmonary fibrosis 57 drugs
- Langerhans-cell histiocytosis 37 drugs
- Pulmonary fibrosis 34 drugs
- Granulomatosis with polyangiitis 36 drugs
- Medulloblastoma 77 drugs
- Ependymoma 56 drugs
- Rhabdoid tumor 52 drugs
- Neuroblastoma 95 drugs
- Glioma 184 drugs
- Osteosarcoma 101 drugs
- Rhabdomyosarcoma 68 drugs
- Sarcoma 204 drugs
Broader categories
- Respiratory disease 57 drugs
- Lung disease 104 drugs
- Skin and connective tissue diseases 3 drugs
- Skin disease 34 drugs
- Connective tissue disease 21 drugs
- Arterial hypertension 119 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D017563 “Lung Diseases, Interstitial”. Prevalence: Orphanet.